H. Lundbeck, interim report for the six months ended 30 June 2004

Today the Supervisory Board of H. Lundbeck A/S approved the company's interim report for the first six months ended 30 June 2004.

Sales of Lundbeck's new drugs accounted for 46% of revenue (excluding the gaboxadol payment).

The overall costs decreased by 6% relative to the year-earlier period.

Profit from operations is still forecast at approximately DKK 2.5 billion, while the forecast for the free cash flow is raised to above DKK 1.6 billion.